Human interferon-γ lacking 23 COOH-terminal amino acids is biologically active  by Sakaguchi, Masao et al.
Volume 230, number 1,2, 201-204 FEB 05728 March 1988 
Human interferon-y lacking 23 COOH-terminal amino acids is 
biologically active 
Masao Sakaguchi, Susumu Honda *, Mariko Ozawa and Osamu Nishimura 
Biotechnology Laboratories and *Applied Microbiology Laboratories, Central Research Division, Takeda Chemicals 
Industries, 2-17-85, Jusohonmachi, Yodogawa-ku, Osaka 532, Japan 
Received 6 February 1988 
We constructed five mutated cDNAs encoding human interferon-y (IFN-y) derivatives lacking 19-23 COOH-terminal 
residues and expressed them in Escherichiu coli. All the derivatives were purified to homogeneity. They showed substan- 
tially the same order of antiviral activity in vitro as the intact molecule, and behaved as a dimer. The far- and near-UV 
circular dichroism spectra of the derivatives were quite similar to those of the intact one. These results indicate that the 
23 COOH-terminal amino acids at least are not essential for achieving the full antiviral activity and constructing the 
higher structure of human IFN-y. 
IFN-y; Antiviral activity; Higher structure 
1. INTRODUCTION 
Interferons (IFNs) possess a variety of biologic 
activities: antiviral, antiproliferative, and im- 
munoregulatory. They are classified into three ma- 
jor groups, IFN-Lu, IFN-fl, and IFN-7, on the basis 
of the antigenicities, cellular origins, and 
biochemical properties [ 11. Among these, IFN-y is 
known to be sensitive to acid treatment [l] and to 
exist as a dimer [2-71. 
Characterization of natural IFN-y demonstrated 
that its COOH-terminal portion is processed to 
several species bearing different COOH-terminal 
amino acids [3,8]. We [6,9] and others [IO,121 
observed that the COOH-terminal portion of the 
recombinant human IFN-7 is also susceptible to 
proteolytic attack. Conflicting results have been 
obtained concerning the minimum structure of the 
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IFN-7124, 123, 122, 121, 120 and 118 represent he human 
IFN-7 derivatives which lack 19, 20, 21, 22, 23 and 25 COOH- 
terminal amino acids, respectively 
COOH-terminal portion necessary for antiviral ac- 
tivity. We [6,9] and Rose et al. [ll] observed that 
15 COOH-terminal amino acids are not essential 
for antiviral activity, whereas Rinderknecht et al. 
[12] and Arakawa et al. [13] reported that the 
COOH-terminal portion is important. 
To investigate further the relation between the 
COOH-terminal structure and the activity of IFN- 
y, we prepared five derivatives lacking the COOH- 
terminal portion and have found that the IFN-7 
derivative is still biologically active, even after 23 
COOH-terminal amino acids are deleted. 
2. MATERIALS AND METHODS 
pLC-2, the expression plasmid of human IFN-y cDNA, was 
a gift from Hoffmann-La Roche Inc. (Nutley, NJ, USA). 
Bacterial strains, Escherichiu coli N4830 (for IFN-7 123 expres- 
sion), DH-l/pRK248 (for expression of all the other IFN-1 
derivatives) and JM-103 (for mutagenesis) were used. 
Mutated cDNA coding for IFN-7123 was constructed by site 
directed mutagenesis as described in [14] and was screened by 
a standard plaque hybridization method [15]. The other 
mutants were constructed with the aid of an ‘oligonucleotide- 
directed in vitro mutagenesis system’ (Amersham, Buckingham- 
shire, England). As shown in fig. 1, the oligonucleotide for IFN- 
7123 was designed to introduce the termination codon (TAG) 
Published by Elsevier Science Publishers B. V. (Biomedical Division) 
00145793/88/$3.50 0 1988 Federation of European Biochemical Societies 201 
Volume 230, number 1,2 FEBS LETTERS March 1988 
120 #*$ 
ATC CCT CAA CTC - TAA TCC TTC TCC 
121 #$# 
NT CAA CTC TCC - TAA TCC TTC TCC 
122 #*# 
CAA CTC TCC CCA - TAA TCC TTC TCC 
123 . . . 
C TCC CCA CCA TAG AAA ACA CC 
124 #$$ 
TCC CCA GCA CCT - TAA TGC TTC TCC 
Fig. 1. Synthetic oligodeoxynucleotides used as a mutagenic 
primer. Numbers indicate those of amino acid residues of IFN- 
y. Dots and asterisks represent mismatched bases and 
termination codon, respectively. 
into position 124 and those for IFN-7124, 122, 121, and 120 
were designed to delete undesired DNA stretches. The 
nucleotide sequences of the altered regions were determined to 
confirm the maintenance of the designed sequence. The con- 
structed cDNAs were inserted into the EcoRI site downstream 
of the XPr-promoter of the pLC-2 vector. 
These derivatives were expressed and purified as described in 
[6] with some modifications. The cell lysate obtained by 7 M 
guanidine hydrochloride (GuHCl) extraction was diluted 
1Cfold with phosphate buffered saline (PBS) containing 1 M 
urea. The mixture was applied to an immunoaffinity column us- 
ing a monoclonal antibody (WN 72-76.53) [16]. The derivative 
was eluted with 20 mM sodium phosphate buffer (pH 7.0) con- 
taining 2 M GuHCl. The eluate was then applied to a Sephacryl 
S-200 (Pharmacia, Uppsala, Sweden) column equilibrated with 
25 mM ammonium acetate (pH 6.0) containing 2 M GuHCl. 
The desired fractions were subjected to dialysis against 25 mM 
ammonium acetate (pH 6.0) for renaturation to yield the active 
derivative. 
Far- and near-UV circular dichroism (CD) spectra were 
measured under constant nitrogen flush at room temperature 
on a J-20A spectropolarimeter with a Data Processor DP-SOIN 
(Jasco, Tokyo, Japan). The mean residue ellipticity, [8], was 
calculated from the calculated mean residue weight of each 
protein. 
The antiviral activity was determined as described in [6]. 
DNA manipulations [15] and SDS-polyacrylamide gel elec- 
trophoresis (SDS-PAGE) [17] were performed as described. 
Protein concentration was determined by the method of Lowry 
et al. [18] using bovine serum albumin as a standard. The amino 
acid composition and COOH-terminal amino acid were deter- 
mined by the standard procedure [6]. To determine the 
molecular masses of the derivatives under nondenaturing condi- 
tions, Sephadex G-100 gel filtration was performed as described 
in [6]. 
3. RESULTS 
To examine the role of the COOH-terminal por- 
tion in IFN-7, we constructed five mutated cDNAs 
encoding IFN-y derivatives lacking 19-23 COOH- 
Table I 
Amino acid compositions of the IFN-7 derivatives 
12 34 5 6 7 
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Fig.2. SDS-PAGE of the intact IFN-7 and its derivatives. 
Proteins were subjected to SDS-PAGE with a 15% gel under 
reducing conditions and the proteins were stained with 
Coomassie brilliant blue R250. Lanes: 1, molecular mass 
markers; 2, IFN-7; 3, IFN-7124; 4, IFN-7123; 5, IFN-~122; 6, 
IFN-7121; 7, IFN-7120. 
Amino 
acid 
Number of residues per molecule 
Intact IFN-7 derivatives 
124 123 122 121 120 
Asx 20 
Thr 4.9 
Ser 9.7 
Glx 19.4 
Pro 2.3 
Gly 5.2 
Val 7.6 
Ala 8.4 
Met 5.1 
Ile 6.7 
Leu 10.4 
Tyr 4.1 
Phe 10.5 
Lys 19.2 
His 1.8 
Arg 8.3 
Trp a 
Cys a 
20 20 20 20 20 
3.8 3.9 3.7 3.8 3.9 
7.6 8.2 6.8 7.2 6.6 
16.9 17.2 17.3 17.2 17.3 
2.0 2.0 2.1 1.0 1.0 
3.5 3.1 3.2 3.2 3.2 
7.8 7.5 7.6 7.5 7.3 
7.3 6.3 5.3 5.2 5.2 
3.7 4.0 3.9 3.8 3.8 
6.0 6.6 6.6 6.5 6.5 
8.8 9.3 9.5 9.5 9.4 
3.9 4.1 4.1 4.1 4.0 
9.1 9.4 9.2 9.3 9.2 
16.3 16.2 17.1 17.0 16.6 
1.8 1.8 1.9 1.8 1.8 
3.0 3.1 3.2 3.1 3.1 
- _ 
_ 
Samples were hydrolyzed in vacua at 1 10°C for 24 h in constant 
boiling HCl containing 4% thioglycolic acid. a, not determined 
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Fig.3. Antiviral activity of the IFN-y derivatives. 
terminal amino acid residues. The IFN-7 
derivatives expressed in E. coli were purified by 
immunoaffinity chromatography, followed by gel 
filtration. The purity of each derivative thus 
purified was assessed by SDS-PAGE and all the 
derivatives gave a single band with a larger mobili- 
ty than the intact one (fig.2). Amino acid analysis 
(table 1) and COOH-terminal amino acid analysis 
by hydrazinolysis (not shown) show that these 
derivatives possess the designed structure. 
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No dramatic change of the activity was observed 
among the intact molecule and the five derivatives 
(fig.3). This result indicates that at least 23 COOH- 
terminal amino acids are not essential for the an- 
tiviral activity. 
Fig.4 shows the CD spectra of IFN-7120, IFN- 
7124, and the intact one. No significant change 
was observed in the either far- (fig.4A) or near-UV 
region (fig4B) in any of them. Two other 
derivatives showed essentially the same CD spec- 
trum (not shown). Gel filtration on a Sephadex 
G-100 column demonstrated that these derivatives 
behaved as a dimer under nondenaturing condi- 
tions (not shown). These results indicate that the 
deletion of at least 23 COOH-terminal amino acids 
affects neither the secondary nor tertiary 
structures. 
4. DISCUSSION 
In preceding papers [6,9], we reported that two 
lower-molecular-mass derivatives (17 kDa and 
15 kDa) lacking 4 and 15 COOH-terminal amino 
acids generated by E. coli protease are as active 
as the intact one. Rose et al. [ 1 l] also pointed out 
that IFN-y lacking 15 COOH-terminal amino acids 
was active. On the other hand, Rinderknecht et al. 
[ 121 and Arakawa et al. [13] indicated that the 
COOH-terminal portion played an important role 
-‘““i 
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Fig.4. CD spectra of the intact IFN-y, IFN-7120 and IFN-~124 in far-UV (A) and near-UV (B) regions. (-) IFN-7; (---) IFN- 
7120; (- - a) IFN-7124. 
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in eliciting antiviral activity. The results described 
in this paper clearly demonstrated that at least 23 
COOH-terminal amino acids are not essential for 
antiviral activity. Though the apparent discrepan- 
cy remains unclear, it may have resulted from a 
difference in the cells used in the assay. The recep- 
tor for IFN-y expressed on some cells might re- 
quire the COOH-terminal portion for interaction. 
The active site of IFN-y, which interacts with 
receptor on cell surface, has not been identified. 
Antibodies against synthetic NHz-terminal pep- 
tides [16,19] neutralize the antiviral activity, while 
antibodies against a synthetic COOH-terminal 
peptide [20] lack the ability to neutralize the activi- 
ty. These observations indicate that the 
NH?-terminal portion, rather than the COOH- 
terminal, might be essential to exert activity. The 
facts that: (i) the COOH-terminal portion is 
susceptible to protease attack [6,9,10,13], (ii) no 
significant change in CD spectra was observed 
among these derivatives and the intact one (fig.4), 
and (iii) that the derivatives behave as dimers, sug- 
gest that this portion might not have an essential 
role in retaining a higher structure. We also con- 
structed IFN-7118, but unfortunately it tends to 
form an insoluble aggregate at the renaturation 
step of the purification and could not be recovered 
(not shown). It is likely that the two residues 
(Glu119 -Leu12’) play a critical role for the folding 
of the protein. 
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